FDA warns stores to stop selling Elf Bar, the top disposable e-cigarette in U.S.

Brasil Notícia Notícia

FDA warns stores to stop selling Elf Bar, the top disposable e-cigarette in U.S.
Brasil Últimas Notícias,Brasil Manchetes
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 45 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 21%
  • Publisher: 97%

It’s the latest attempt by regulators to crack down on illegal disposable vapes that have poured into U.S. stores in recent years.

WASHINGTON — The Food and Drug Administration on Thursday said it has sent warning letters to dozens of retailers selling fruit- and candy-flavored disposable e-cigarettes, including the current best-selling brand, Elf Bar.

In the latest action, the FDA said it issued warnings to 189 convenience stores, vape shops and other retailers. The Centers for Disease Control and Prevention analysis showed the number of e-cigarette brands in the U.S. grew from 184 in early 2020 to 269 by late 2022. Elf Bar was the best-selling disposable in the U.S. and the third-best selling e-cigarette by late last year. Only the reusable e-cigarettes Vuse, from Reynolds American, and Juul had higher sales.

Brand information was not reported in 95% of cases, but when it was, Elf Bar was the most frequently named product. Manufactured by a Chinese firm, iMiracle Shenzhen, Elf Bar is part of a wave of copycat e-cigarettes that have followed a path paved by Puff Bar, a popular brand of disposables that briefly racked up hundreds of millions in sales after regulators cracked down on older vaping products like Juul.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

MarketWatch /  🏆 3. in US

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

FDA warns stores to stop selling Elf Bar, the top disposable e-cigarette in the USFDA warns stores to stop selling Elf Bar, the top disposable e-cigarette in the USU.S. regulators have sent warning letters to dozens of retailers selling fruity disposable e-cigarettes, including the current best-selling brand, Elf Bar
Consulte Mais informação »

FDA warns stores to stop selling Elf Bar, the top disposable e-cigarette in the USFDA warns stores to stop selling Elf Bar, the top disposable e-cigarette in the USU.S. regulators have sent warning letters to dozens of retailers selling fruity disposable e-cigarettes, including the current best-selling brand, Elf Bar. The action Thursday is the Food and Drug Administration's latest attempt to crack down on illegal disposable vapes that have poured into U.S. stores in recent years. The FDA has tried for years to regulate the multibillion-dollar vaping industry. But new illegal products continue to launch. A new separate government report finds there are now 269 different e-cigarette brands sold in the U.S. Elf Bar was the best-selling disposable brand. It comes in fruit and candy flavors that regulators say appeal to underage users.
Consulte Mais informação »

New Austin bar 'Sign Bar' now open featuring 75+ signs from legendary local businessesNew Austin bar 'Sign Bar' now open featuring 75+ signs from legendary local businessesFeeling a little nostalgic? A new Austin bar displaying over 75 classic signs from legendary local businesses across the city is now open.
Consulte Mais informação »

FDA Warns of Tattoo Ink Tied to Dangerous InfectionsFDA Warns of Tattoo Ink Tied to Dangerous InfectionsThe FDA released the new draft guidance aiming to reduce the use of pathogen-contaminated tattoo ink, which can cause stubborn infections that are especially hard to treat, dermatologists said.
Consulte Mais informação »

FDA OKs Empagliflozin for Children With Type 2 DiabetesFDA OKs Empagliflozin for Children With Type 2 DiabetesThe FDA has approved empagliflozin and empagliflozin combined with metformin for the treatment of type 2 diabetes in children aged 10 years and older.
Consulte Mais informação »

FDA Approves Talazoparib for Metastatic Prostate CancerFDA Approves Talazoparib for Metastatic Prostate CancerThe oral PARP inhibitor talazoparib in combination with enzalutamide provides a new treatment option for patients with HRR gene–mutated metastatic castration-resistant prostate cancer.
Consulte Mais informação »



Render Time: 2025-02-26 08:51:30